GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Beneish M-Score

Fennec Pharmaceuticals (Fennec Pharmaceuticals) Beneish M-Score : 7.54 (As of Jun. 06, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 7.54 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Fennec Pharmaceuticals's Beneish M-Score or its related term are showing as below:

FENC' s Beneish M-Score Range Over the Past 10 Years
Min: 7.54   Med: 7.86   Max: 8.18
Current: 7.54

During the past 13 years, the highest Beneish M-Score of Fennec Pharmaceuticals was 8.18. The lowest was 7.54. And the median was 7.86.


Fennec Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Fennec Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Beneish M-Score Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 8.18

Fennec Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 8.18 7.54

Competitive Comparison of Fennec Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Fennec Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Beneish M-Score falls into.



Fennec Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Fennec Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4362+0.528 * 0.9811+0.404 * 2.0269+0.892 * 13.995+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1046+4.679 * -0.355166-0.327 * 0.4454
=7.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $10.27 Mil.
Revenue was 25.377 + 9.735 + 6.515 + 3.325 = $44.95 Mil.
Gross Profit was 24.827 + 9.05 + 6.184 + 3.177 = $43.24 Mil.
Total Current Assets was $68.17 Mil.
Total Assets was $69.19 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.94 Mil.
Selling, General, & Admin. Expense(SGA) was $36.94 Mil.
Total Current Liabilities was $9.84 Mil.
Long-Term Debt & Capital Lease Obligation was $31.35 Mil.
Net Income was 12.837 + -2.682 + -1.867 + -5.444 = $2.84 Mil.
Non Operating Income was -0.049 + 0.006 + -0.024 + 0.005 = $-0.06 Mil.
Cash Flow from Operations was 39.047 + -4.86 + -2.76 + -3.946 = $27.48 Mil.
Total Receivables was $1.68 Mil.
Revenue was 1.677 + 1.535 + 0 + 0 = $3.21 Mil.
Gross Profit was 1.582 + 1.449 + 0 + 0 = $3.03 Mil.
Total Current Assets was $21.66 Mil.
Total Assets was $21.82 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.19 Mil.
Selling, General, & Admin. Expense(SGA) was $25.25 Mil.
Total Current Liabilities was $4.02 Mil.
Long-Term Debt & Capital Lease Obligation was $25.14 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(10.274 / 44.952) / (1.683 / 3.212)
=0.228555 / 0.523973
=0.4362

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.031 / 3.212) / (43.238 / 44.952)
=0.943649 / 0.96187
=0.9811

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (68.171 + 0) / 69.193) / (1 - (21.662 + 0) / 21.821)
=0.01477 / 0.007287
=2.0269

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=44.952 / 3.212
=13.995

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.186 / (0.186 + 0)) / (0.938 / (0.938 + 0))
=1 / 1
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(36.941 / 44.952) / (25.246 / 3.212)
=0.821788 / 7.8599
=0.1046

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((31.349 + 9.836) / 69.193) / ((25.14 + 4.02) / 21.821)
=0.595219 / 1.336327
=0.4454

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2.844 - -0.062 - 27.481) / 69.193
=-0.355166

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Fennec Pharmaceuticals has a M-score of 7.67 signals that the company is likely to be a manipulator.


Fennec Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (Fennec Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Robert Andrade officer: Chief Financial Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Rosty Raykov director, officer: Chief Executive Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh director 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Marco Maria Brughera director VIALE STEFINI 14, MILANO L6 00000
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel officer: Chief Commercial Officer 1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp 10 percent owner 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook director PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040